Jump Financial LLC Has $2.95 Million Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Jump Financial LLC raised its holdings in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 64.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 114,902 shares of the company's stock after buying an additional 45,035 shares during the period. Jump Financial LLC owned about 0.13% of IDEAYA Biosciences worth $2,953,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of IDYA. XTX Topco Ltd acquired a new position in IDEAYA Biosciences during the third quarter valued at approximately $245,000. Barclays PLC lifted its position in IDEAYA Biosciences by 188.8% during the third quarter. Barclays PLC now owns 181,170 shares of the company's stock valued at $5,739,000 after buying an additional 118,438 shares in the last quarter. Geode Capital Management LLC lifted its position in IDEAYA Biosciences by 9.8% during the third quarter. Geode Capital Management LLC now owns 1,945,455 shares of the company's stock valued at $61,645,000 after buying an additional 172,838 shares in the last quarter. JPMorgan Chase & Co. lifted its position in IDEAYA Biosciences by 17.8% during the third quarter. JPMorgan Chase & Co. now owns 79,780 shares of the company's stock valued at $2,527,000 after buying an additional 12,029 shares in the last quarter. Finally, SG Americas Securities LLC lifted its position in IDEAYA Biosciences by 444.2% during the fourth quarter. SG Americas Securities LLC now owns 18,486 shares of the company's stock valued at $475,000 after buying an additional 15,089 shares in the last quarter. 98.29% of the stock is owned by institutional investors and hedge funds.

IDEAYA Biosciences Trading Up 4.8 %

IDYA stock traded up $0.89 during trading on Wednesday, hitting $19.52. The company had a trading volume of 636,167 shares, compared to its average volume of 1,107,281. IDEAYA Biosciences, Inc. has a fifty-two week low of $13.45 and a fifty-two week high of $44.42. The firm has a market capitalization of $1.71 billion, a price-to-earnings ratio of -5.92 and a beta of 0.51. The business has a 50 day moving average of $18.11 and a 200 day moving average of $23.65.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last released its earnings results on Thursday, February 13th. The company reported ($1.49) EPS for the quarter, missing the consensus estimate of ($0.67) by ($0.82). The company had revenue of $7.00 million for the quarter, compared to analyst estimates of $7.00 million. As a group, equities analysts predict that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current year.

Analyst Ratings Changes

A number of research firms have recently issued reports on IDYA. Cantor Fitzgerald reiterated an "overweight" rating on shares of IDEAYA Biosciences in a research note on Monday, January 13th. Royal Bank of Canada reiterated an "outperform" rating and set a $61.00 price objective on shares of IDEAYA Biosciences in a research note on Wednesday, January 15th. Finally, Stephens reiterated an "overweight" rating and set a $50.00 price objective on shares of IDEAYA Biosciences in a research note on Friday, February 14th. Two equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $53.58.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.